136 results about "Myosin" patented technology

The invention provides the construction for a farnesyl pyrophosphoric acid synthetase RNA (Ribonucleic Acid) interference recombinant lentivirus vector, which comprises the following steps of: sieving the most effective target sequence of an FDS (farnesyl diphosphate synthase) gene RNAi (RNA interference) in a tool cell 293T cell, synthesizing the double-stranded DNA of the most effective target sequence, connecting to a pGCSIL-GFP vector and successfully constructing the recombinant vector through enzyme cutting, sequencing and identification. Researches indicate that the constructed RNA interference vector LV-sh-FDS can downwards modulate the expression of an FDS mRNA (Messenger RNA) level in a neonatal rat cardiac myocyte, simultaneously can downwards modulate the expression of myocardial hypertrophy markers such as cell areas and marker genes beta-MHC (Myosin Heavy Chain) and BNP (Brain Natriuretic Peptide), additionally can effectively inhabit the activity of RhoA while downwards modulating the FDS, can be applied in preparing medicaments for treating myocardial hypertrophy diseases and also can be applied in preparing medicaments for cholesterol metabolic control.

This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, Glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the methods, processes, compounds and compositions are also for anti-angiogenesis; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer.

The present invention relates to Myosin II ATPase inhibitor compounds, including substituted 3a-hydroxy-1, 2, 3, 3a-tetrahydro-4H-pyrrolo [2,3b] quinolin-4-one compounds which are blebbistatin derivatives.

The invention relates to the field of medicinal chemistry, in particular to a myosin inhibitor, as well as a preparation method and application thereof. The invention provides a compound or pharmacologically acceptable salt, an isomer, a prodrug, a polymorphic substance or a solvate thereof. A chemical structural formula of the compound is as shown in a formula I. Compared with other similar medicines in the prior art, the compound or the pharmacologically acceptable salt, the isomer, the prodrug, the polymorphic substance or the solvate thereof provided by the invention have better activity and a more ideal pharmacokinetics characteristic.

The invention discloses a process for simultaneously preparing an antioxidative peptide and an antifreeze peptide through enzymolysis of collagens. The method comprises the following steps: extractingcollagens by taking salmon skin as a raw material, hydrolyzing the collagens into a short peptide solution by utilizing crude enzymes of extracellaluar protease obtained by fermentation of Vibrio sp.SQS2-3, performing centrifugal ultrafiltration by a 3000 Da ultrafiltration tube 4500*g for 45 minutes so as to obtain the antifreeze peptide with effects of protecting myosin and relieving decreaseof Ca<2+>-ATPase activity in multigelation, performing Sephadex LH-20 gel filtration chromatography to separate lower ultrafiltration components so as to obtain the antioxidative peptide which has effects of scavenging DPPH free radicals and hydroxyl radicals and a certain ability of inhibiting DNA oxidative damage and shows concentration-dependent antioxidant activity in oxygen radical absorptioncapacity detection. The LC-MS technology shows that the antioxidant component contains 19 polypeptides.

A method for diagnosing the likelihood and severity of cardiovascular disease in a patient is disclosed. The method determines the levels of antibodies against autoantigens, including myosin, oxidized LDL, β-2-glycoprotein, heat shock protein-60, platelet glycoprotein, and immune complexes. It then compares the results to normal levels to determine the likelihood and severity of cardiovascular disease.

Inhibitors of myosin activity are used to treat or prevent a fibrotic disorder of the eye, for example posterior capsule opacification (PCO).

The invention relates to a method for the microdetermination of ATPase activity of myoglobulin, and the method is characterized in that based on the reaction method of a classic molybdenum blue method, the molar ratio of ATP (adenosine-triphosphate) to myoglobulin is controlled at 2000:1 and the molar ratio of ammonium molybdate to stannous chloride is controlled at 5.5:1. The determination method provided by the invention is simple, convenient, fast, high in response value and wide in linear range, and can be applied to the screening of inhibitors. The invention discloses an application of Ruscogenin in inhibiting the ATPase activity of the myoglobulin.

The invention relates to a separation and purification method of high-purity porcine muscle stem cells, for research and production of cultured meat. The separation and purification method disclosed by the invention comprises the steps of obtaining sterile muscular tissue, efficiently digesting the muscular tissue to obtain a large quantity of muscle mononuclear cells, and finally performing steaming cell sorting to obtain the high-purity porcine muscle stem cells. The invention further discloses a method for efficiently digesting the porcine muscular tissue. By the method, the digestion speedand the digestion intensity can be increased, and a large quantity of muscle mononuclear cells can be obtained. When the purification method disclosed by the invention is applied, the porcine musclestem cells of which the purity exceeds 92% (by PAX7) can be stably obtained. The porcine muscle stem cells obtained through separation have efficient disintegration efficiency, and MYOSIN expression quantity can reach 85%-90%. When the method disclosed by the invention is applied, a large quantity of seed cell sources can be provided for research and actual production of the cultured meat.

The invention belongs to the technical field of pig molecular marker preparation and particularly relates to a genetic marker using pig MLC(myosin light chain)2 5' flanking promoter segments as pig carcass traits as well as a preparation method and application of the genetic marker. The genetic marker has the nucleotide sequence shown as SEQ ID NO (sequencer identifier number):1 and SEQ ID NO:2 in a sequence table. One A/G mutation and one G/A mutation respectively exist at the 53bp part of the sequence shown as SEQ ID NO:1 and SEQ ID NO:2, and the polymorphism of DraIII-RFLP is caused by the allele mutation. The genetic marker is used for carrying out pig carcass traits correlation analysis on large white pig and meishan pig F2 generations, and the transcriptional activity of promoters in different genotypes is detected. The invention also discloses a parting detection method of the genetic marker, and the novel genetic marker and the detection method are provided for the pig carcass traits molecular marker auxiliary selection.

The invention discloses a method for heterologously expressing active membrane proteins by using a Pichia pastoris expression system. The invention relates to a method for expressing a myosin cross-reactive antigen (MCRA) of Bifidobacterium BB-12 in a recombinant mode and an expression host used in the method. The expression host is a PichiaPinkTM expression system transformed from pPink alpha-HC-MCRA plasmid. The invention also relates to application of an MCRA of Bifidobacterium BB-12 or an expression host in preparing conjugated linoleic acid.

The invention discloses a method for purifying myoblast derived from bovine fetus skeletal muscle tissue. The method is characterized in that the material used by the method is the longissimus dorsi muscle tissue of a 3-month-old bovine fetus, and reagents used by the method are horse serum, anti-fast muscle myosin heavy chain antibodies, collagenase, fetal bovine serum, a low-sugar Dulbecco modified Eagle medium, a cell-sorting buffer solution and anti-platelet derived growth factor receptor alpha antibodies.

The invention relates to the technical field of quality improvement on aquatic products, in particular to a method for maintaining the liquid state of high concentration myosin at high temperature. The method comprises the following specific steps: firstly, selecting back fish flesh, cleaning and peeling; extracting to obtain a myosin solution, and determining the protein content as 10 to 20 mg/mL; adding arginine, lysine or histidine into the extracted myosin solution, wherein the final concentration is 10 to 100 mM; then carrying out two-stage heating, firstly heating at 40 DEG C for 60 minand then heating at 90 DEG C for 30 min, thus maintaining the liquid state of the high concentration myosin at high temperature. The method disclosed by the invention has the advantages of simple operation, high economic benefits and broad prospects; a foundation is laid for liquid fish protein products.

This invention provides a method for producing a plant with enhanced or suppressed growth through introduction of a mutated gene and a plant including such a mutated gene. This invention provides a method for producing a plant with enhanced growth or suppressed growth. Such method includes a step of introducing a gene encoding a chimeric myosin protein into a host plant so as to transform the host plant, wherein the chimeric myosin protein comprises: a neck domain, a coiled-coil domain, and a globular tail domain from a myosin protein involved in cytoplasmic streaming of a donor plant; and a motor domain from a myosin protein other than the myosin protein of the host plant, which has sliding velocity that is higher or lower, respectively, than that of the myosin protein involved in cytoplasmic streaming of the donor plant.

The invention discloses a soluble protein aggregation nanoparticle preparation method and application. The preparation method comprises the following steps that myosin is extracted; a myosin solutionis prepared; the pH of the solution is adjusted; water-bath heating is conducted; after cooling is conducted to reach the room temperature, the pH is set to be the original pH, and then soluble myosinaggregation nanoparticles can be obtained; meanwhile, by means of the obtained soluble myosin aggregation nanoparticles, soybean oil is emulsified, and the emulsification effect is better compared with a stable emulsion of ordinary myosin aggregates. The myosin aggregation nanoparticles obtained through the method are high in solubility, small in particle size, good in emulsifying property and applicable to industries of food, medicine, cosmetics and the like.

The invention discloses a dried salted yellow croaker myosin antibacterial peptide LCM13. The amino acid sequence of the dried salted yellow croaker myosin antibacterial peptide LCM13 is VSIYKLTGAVMHYGNMKFK. The molecular weight of the antibacterial peptide is 2186 Da. The invention also discloses an application of the antibacterial peptide of the dried salted myosin of the yellow croaker, namely application in preventing or treating bacterial infection of algicidal vibrio, vibrio parahaemolyticus and the like. The invention lays a foundation for the subsequent further research of the salted yellow croaker myosin antibacterial peptide as a food preservative and the development of a feed additive for preventing fish diseases.

The invention provides application of a myosin-5 gene Myo5 segment to prevention and treatment of plant fungal diseases and/or enhancement of plant disease resistance. Myosin-5 gene is derived from fusarium graminearum, fusarium asiaticum, fussrium moniliforme, fusarium oxysporum, magnaporthe oryzae, botrytis cinerea, verticillium dahliae or sclerotinia sclerotiorum. The myosin-5 gene Myo5 segmentis siRNA of 15-30nt randomly generated after the combination of an Myo5dsRNA segment and a dsRNA segment or full-length or partial Myo5dsRNA is subjected to RNase digestion. The invention also provides an in vitro interference preparation containing the myosin-5 gene Myo5 segment. The myosin-5 gene Myo5 RNA interference technology has the green and safe outstanding advantages that the drug sensitivity of pathogenic fungi is improved, the drug resistance level is reduced, the pathogenicity is interfered, the disease resistance of plants is enhanced, and the specificity of plant diseases is prevented and treated.

The invention discloses an assay kit for testing the relative expression of core-binding factor (CBF) beta/myosin 11 fusion genes, and the kit comprises red blood cell lysis buffer, TRIzol, chloroform, absolute ethyl alcohol, ReverTraAceqPCRRTKit, testing system polymerase chain reaction (PCR) reaction solution, positive control substance and negative control substance, and is characterized in that the testing system PCR reaction solution comprises THUNDERBIRDqPCRMIX, primers of CBF beta/MYH11-F, CBF beta/MYH11-A-R, CBF beta/MYH11-D-R and CBF beta/MYH11-E-R for amplifying a target gene, probe of CBF beta/MYH11-Prob, primers of abl-F and abl-R for amplifying an internal control gene, and probe of abl-Probe. The assay kit can be used for testing the expression level of the CBF beta/myosin 11 fusion genes of a patient suffering from human acute myelognous leukemia (AML), so the test time can be effectively saved, and the test precision is improved.

The present invention relates compositions and methods for meat tenderization by contacting meat with a protease that has higher activity on the meat proteins troponin and myosin as compared to the meat proteins actin and collagen. The present invention also relates to screening methods for identifying enzymes suitable for use in tenderizing meat.

Provided are methods of treating an overactive bladder in a patient which include: administering a Myosin II ATPase inhibitor compound; or administering an X group and Y group substituted (3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrollo[2, 3b] quinolin-4-one) compound of Formula 1 or administering an X group and Y group substituted (3a-hydroxy-1-phenyl-1,2,3,3a-tetrahydro-4H-pyrollo[2,3b] quinolin-4-one) compound of Formula II; or administering pharmaceutically-acceptable salts, racemic mixtures, enantiomers, or prodrugs of said compounds, useful in their active form as inhibitors of Myosin H ATPase related to over-active bladder. Optionally the compounds are administered intervesicularly into the bladder. Also provided are pharmaceutical compositions comprising said compounds useful in their active form, as methods of treating a patient suffering from an over-active bladder related to inhibition of Myosin II ATPase. These pharmaceutical compositions also may contain one or more other compounds useful in their active form, as methods of treating a patient suffering from an over-active bladder.